A prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem etzadroxil/probenecid versus oral amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult women.
To compare the overall response (clinical and microbiologic combined response) at Day 12 (±1 day)/test of cure (TOC) of oral sulopenem etzadroxil/probenecid tablets (500 mg/500 mg) versus oral amoxicillin/clavulanate (875 mg/125 mg) tablets for the treatment of uncomplicated urinary tract infection in adult women.
Primary Investigator: Mickey Karram